LM
Lori Muffly
Research areas: Medicine · Hematology · CAR-T cell therapy research · Hematopoietic Stem Cell Transplantation · Acute Lymphoblastic Leukemia research
0000-0002-9887-6136
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (402)
- Travel time, insurance, and specialized cancer care for adolescents and young adults with acute lymphoblastic leukemia Save
- Philadelphia chromosome-like acute lymphoblastic leukemia: treat intensively, transplant selectively. Save
- Incidence and risk factors for CNS relapse in adult ALL after allogeneic hematopoietic cell transplantation Save
- Trends and Predictors of Hematopoietic Cell Transplant Utilization for HIV-lymphoma in California, 1991-2016. Save
- Differences in Hematopoietic Cell Transplantation Outcomes by HIV status, California, 1991-2016. Save
- A secret-shopper study evaluating logistic barriers to care among young adults with acute lymphoblastic leukemia Save
- CAR T before the storm: early consolidation in B-ALL Save
- Long-term follow-up of a pediatric regimen for AYA with Ph-negative ALL: 10-year survival of CALGB 10403 (alliance) Save
- Long-term lessons from CALGB 10403 Save
- Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients. Save
- Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study Save
- Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML. Save
- A QUEST to improve outcomes for adults with high-risk B-ALL Save
- Data from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia Save
- Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia Save
- Supplemental Figure 1 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia Save
- Supplemental Figure 2 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia Save
- Supplemental Figure 2 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia Save
- Supplemental Figure 3 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia Save
- Supplemental Figure 3 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia Save